Ashion Analytics Introduces GEM Cancer Panel
Ashion Analytics has introduced its new Genomic Enabled Medicine cancer panel to uncover true tumor-specific alterations by comparing the sequence of the tumor against the paired normal DNA from each patient.
The cancer panel sequences the coding regions of 562 cancer-related genes, according to Ashion, and provides a detailed genomic analysis of a patient's cancer.
It also features high sensitivity for detecting point mutations, and a turnaround time of 10 to 14 days.
Ashion, headquartered in Phoenix, Ariz., works to develop personalized medicine diagnostics, data analytics, and clinical coordination services. — Michael Cipriano